|
1
|
Benjamin EJ, Levy D, Vaziri SM, D’Agostino
RB, Belanger AJ and Wolf PA: Independent risk factors for atrial
fibrillation in a population-based cohort. The Framingham Heart
Study. JAMA. 271:840–844. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang J, Shen F, Fang W, Liu X and Yang
YQ: Novel GATA4 mutations in lone atrial fibrillation. Int J Mol
Med. 28:1025–1032. 2011.PubMed/NCBI
|
|
3
|
Fatini C, Sticchi E, Gensini F, Gori AM,
Marcucci R, Lenti M, Michelucci A, Genuardi M, Abbate R and Gensini
GF: Lone and secondary nonvalvular atrial fibrillation: role of a
genetic susceptibility. Int J Cardiol. 120:59–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang YQ, Liu X, Zhang XL, Wang XH, Tan HW,
Shi HF, Jiang WF and Fang WY: Novel connexin40 missense mutations
in patients with familial atrial fibrillation. Europace.
12:1421–1427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang Y, Xia M, Jin Q, Bendahhou S, Shi J,
Chen Y, Liang B, Lin J, Liu Y, Liu B, et al: Identification of a
KCNE2 gain-of-function mutation in patients with familial atrial
fibrillation. Am J Hum Genet. 75:899–905. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Belluzzi F, Sernesi L, Preti P, Salinaro
F, Fonte ML and Perlini S: Prevention of recurrent lone atrial
fibrillation by the angiotensin-II converting enzyme inhibitor
ramipril in normotensive patients. J Am Coll Cardiol. 53:24–29.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tayebjee MH, Creta A, Moder S, Hunter RJ,
Earley MJ, Dhinoja MB and Schilling RJ: Impact of
angiotensin-converting enzyme-inhibitors and angiotensin receptor
blockers on long-term outcome of catheter ablation for atrial
fibrillation. Europace. 12:1537–1542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Klemm HU, Heitzer T, Ruprecht U, Meinertz
T and Ventura R: Impact of angiotensin-converting enzyme inhibitors
and angiotensin II receptor blockers on the long-term outcome after
pulmonary vein isolation for paroxysmal atrial fibrillation.
Cardiology. 117:14–20. 2010. View Article : Google Scholar
|
|
9
|
Marchesi C, Paradis P and Schiffrin EL:
Role of the reninangiotensin system in vascular inflammation.
Trends Pharmacol Sci. 29:367–374. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rahman ST, Lauten WB, Khan QA, Navalkar S,
Parthasarathy S and Khan BV: Effects of eprosartan versus
hydrochlorothiazide on markers of vascular oxidation and
inflammation and blood pressure (renin-angiotensin system
antagonists, oxidation, and inflammation). Am J Cardiol.
89:686–690. 2002. View Article : Google Scholar
|
|
11
|
Kumagai K, Nakashima H, Urata H, Gondo N,
Arakawa K and Saku K: Effects of angiotensin II type 1 receptor
antagonist on electrical and structural remodeling in atrial
fibrillation. J Am Coll Cardiol. 41:2197–2204. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakashima H, Kumagai K, Urata H, Gondo N,
Ideishi M and Arakawa K: Angiotensin II antagonist prevents
electrical remodeling in atrial fibrillation. Circulation.
101:2612–2617. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Danser AH, Schalekamp MA, Bax WA, van den
Brink AM, Saxena PR, Riegger GA and Schunkert H:
Angiotensin-converting enzyme in the human heart. Effect of the
deletion/insertion polymorphism. Circulation. 92:1387–1388. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rigat B, Hubert C, Alhenc-Gelas F, Cambien
F, Corvol P and Soubrier F: An insertion/deletion polymorphism in
the angiotensin I-converting enzyme gene accounting for half the
variance of serum enzyme levels. J Clin Invest. 86:1343–1346. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Watanabe H, Kaiser DW, Makino S, MacRae
CA, Ellinor PT, Wasserman BS, Kannankeril PJ, Donahue BS, Roden DM
and Darbar D: ACE I/D polymorphism associated with abnormal atrial
and atrioventricular conduction in lone atrial fibrillation and
structural heart disease: implications for electrical remodeling.
Heart Rhythm. 6:1327–1332. 2009. View Article : Google Scholar
|
|
16
|
White PC and Slutsker L: Haplotype
analysis of CYP11B2. Endocr Res. 21:437–442. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brand E, Chatelain N, Mulatero P, Fery I,
Curnow K, Jeunemaitre X, Corvol P, Pascoe L and Soubrier F:
Structural analysis and evaluation of the aldosterone synthase gene
in hypertension. Hypertension. 32:198–204. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goette A, Hoffmanns P, Enayati W,
Meltendorf U, Geller JC and Klein HU: Effect of successful
electrical cardioversion on serum aldosterone in patients with
persistent atrial fibrillation. Am J Cardiol. 88:906–909. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amir O, Amir RE, Paz H, Mor R, Sagiv M and
Lewis BS: Aldosterone synthase gene polymorphism as a determinant
of atrial fibrillation in patients with heart failure. Am J
Cardiol. 102:326–329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Husser D, Adams V, Piorkowski C, Hindricks
G and Bollmann A: Chromosome 4q25 variants and atrial fibrillation
recurrence after catheter ablation. J Am Coll Cardiol. 55:747–753.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Liu X, Shi H, Tan H, Jiang W, Wang
Y, Yang G and Zhou L: Early recurrences after paroxysmal atrial
fibrillation ablation: when is the proper timing for reablation?
Pacing Clin Electrophysiol. 34:709–716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu X, Tan H, Wang X, Shi H, Li Y, Li F,
Zhou L and Gu J: Efficacy of catheter ablation and surgical
CryoMaze procedure in patients with long-lasting persistent atrial
fibrillation and rheumatic heart disease: a randomized trial. Eur
Heart J. 31:2633–2641. 2010. View Article : Google Scholar
|
|
23
|
Lang RM, Bierig M, Devereux RB,
Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward
J, Shanewise J, et al: Recommendations for chamber quantification.
Eur J Echocardiogr. 7:79–108. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ravn LS, Benn M, Nordestgaard BG, Sethi
AA, Agerholm-Larsen B, Jensen GB and Tybjaerg-Hansen A:
Angiotensinogen and ACE gene polymorphisms and risk of atrial
fibrillation in the general population. Pharmacogenet Genomics.
18:525–533. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roux JF, Zado E, Callans DJ, Garcia F, Lin
D, Marchlinski FE, Bala R, Dixit S, Riley M, Russo AM, et al:
Antiarrhythmics after ablation of atrial fibrillation (5A study).
Circulation. 120:1036–1040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Balk EM, Garlitski AC, Alsheikh-Ali AA,
Terasawa T, Chung M and Ip S: Predictors of atrial fibrillation
recurrence after radio-frequency catheter ablation: a systematic
review. J Cardiovasc Electrophysiol. 21:1208–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fogari R, Derosa G, Ferrari I, Corradi L,
Zoppi A, Lazzari P, Santoro T, Preti P and Mugellini A: Effect of
valsartan and ramipril on atrial fibrillation recurrence and P-wave
dispersion in hypertensive patients with recurrent symptomatic lone
atrial fibrillation. Am J Hypertens. 21:1034–1039. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Staszewsky L, Wong M, Masson S, Raimondi
E, Gramenzi S, Proietti G, Bicego D, Emanuelli C, Pulitanò G,
Taddei F, et al: Left atrial remodeling and response to valsartan
in the prevention of recurrent atrial fibrillation: the GISSI-AF
echo-cardiographic substudy. Circ Cardiovasc Imaging. 4:721–728.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin SH, Park MY, Oh WJ, Hong SJ, Pak HN,
Song WH, Lim DS, Kim YH and Shim WJ: Left atrial volume is a
predictor of atrial fibrillation recurrence after catheter
ablation. J Am Soc Echocardiogr. 21:697–702. 2008.PubMed/NCBI
|
|
30
|
Arriagada G, Berruezo A, Mont L, Tamborero
D, Molina I, Coll-Vinent B, Vidal B, Sitges M, Berne P and Brugada
J; GIRAFA (Grup Integrat de Recerca en Fibril.lació Auricular)
Investigators: Predictors of arrhythmia recurrence in patients with
lone atrial fibrillation. Europace. 10:9–14. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brasier AR, Recinos A III and Eledrisi MS:
Vascular inflammation and the renin-angiotensin system.
Arterioscler Thromb Vasc Biol. 22:1257–1266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang M, Gai X, Yang X, Hou J, Lan X,
Zheng W, Chen F and He J: Functional polymorphisms in ACE and
CYP11B2 genes and atrial fibrillation in patients with hypertensive
heart disease. Clin Chem Lab Med. 47:32–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barbato A, Russo P, Siani A, Folkerd EJ,
Miller MA, Venezia A, Grimaldi C, Strazzullo P and Cappuccio FP:
Aldosterone synthase gene (CYP11B2) C−344T polymorphism, plasma
aldosterone, renin activity and blood pressure in a multi-ethnic
population. J Hypertens. 22:1895–1901. 2004.
|
